Molecular basis of interferon resistance in hepatitis C virus

Current Opinion in Virology

Volumn 8, Issue , 2014, Pages 38-44

  Perales, Celia ^a,b   Beach, Nathan M ^a   Sheldon, Julie ^a,c   Domingo, Esteban ^a,b  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; VIRUS PROTEIN; ANTIVIRUS AGENT;

ALLELE; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CELL CULTURE; GENE MUTATION; HEPATITIS C VIRUS; HOST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; AMINO ACID SUBSTITUTION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MISSENSE MUTATION; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MUTATION, MISSENSE; VIRAL PROTEINS;

EID: 84903317598     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.05.003     Document Type: Review

References (56)

1. S.M. Horner, and M. Gale Jr. Regulation of hepatic innate immunity by hepatitis C virus Nat Med 19 2013 879 888
2. S.H. Park, and B. Rehermann Immune responses to HCV and other hepatitis viruses Immunity 40 2014 13 24
3. M.H. Heim Interferons and hepatitis C virus Swiss Med Wkly 142 2012 w13586
4. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485 1492
5. K.J. Cummings, S.M. Lee, E.S. West, J. Cid-Ruzafa, S.G. Fein, Y. Aoki, M.S. Sulkowski, and S.N. Goodman Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials JAMA 285 2001 193 199
6. A.M. Di Bisceglie, J. Thompson, N. Smith-Wilkaitis, E.M. Brunt, and B.R. Bacon Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon Hepatology 33 2001 704 707
7. T. Taniguchi, and A. Takaoka The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors Curr Opin Immunol 14 2002 111 116
8. R.M. Welsh, K. Bahl, H.D. Marshall, and S.L. Urban Type 1 interferons and antiviral CD8 T-cell responses PLoS Pathog 8 2012 e1002352
9. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, H. Ishikawa, H. Watanabe, F. McPhee, E. Hughes, and H. Kumada Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
10. C. Sarrazin, C. Hezode, S. Zeuzem, and J.M. Pawlotsky Antiviral strategies in hepatitis C virus infection J Hepatol 56 Suppl1 2012 S88 S100
11. T.K. Scheel, and C.M. Rice Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat Med 19 2013 837 849
12. D.L. Wyles Antiviral resistance and the future landscape of hepatitis C virus infection therapy J Infect Dis 207 Suppl1 2013 S33 S39
13. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, and M. Wind-Rotolo et al. Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
14. J. Friborg, S. Levine, C. Chen, A.K. Sheaffer, S. Chaniewski, S. Voss, J.A. Lemm, and F. McPhee Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication Antimicrob Agents Chemother 57 2013 1312 1322
15. M. Sarasin-Filipowicz, E.J. Oakeley, F.H. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M.H. Heim Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci U S A 105 2008 7034 7039
16. M.H. Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nat Rev Immunol 13 2013 535 542
17. J.W. Schoggins, S.J. Wilson, M. Panis, M.Y. Murphy, C.T. Jones, P. Bieniasz, and C.M. Rice A diverse range of gene products are effectors of the type I interferon antiviral response Nature 472 2011 481 485
18. J.W. Schoggins, and C.M. Rice Interferon-stimulated genes and their antiviral effector functions Curr Opin Virol 1 2011 519 525
19. P.S. Pang, P.J. Planet, and J.S. Glenn The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy PLoS One 4 2009 e6579
20. E. Domingo, J. Sheldon, and C. Perales Viral quasispecies evolution Microbiol Mol Biol Rev 76 2012 159 216
21. J.C. de la Torre, and J.J. Holland RNA virus quasispecies populations can suppress vastly superior mutant progeny J Virol 64 1990 6278 6281
22. C. González-López, A. Arias, N. Pariente, G. Gómez-Mariano, and E. Domingo Preextinction viral RNA can interfere with infectivity J Virol 78 2004 3319 3324
23. S. Crowder, and K. Kirkegaard Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses Nat Genet 37 2005 701 709
24. A. Grande-Pérez, E. Lazaro, P. Lowenstein, E. Domingo, and S.C. Manrubia Suppression of viral infectivity through lethal defection Proc Natl Acad Sci USA 102 2005 4448 4452
25. C. Perales, R. Mateo, M.G. Mateu, and E. Domingo Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants J Mol Biol 369 2007 985 1000
26. V. Martin, D. Abia, E. Domingo, and A. Grande-Perez An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis J Gen Virol 91 2010 990 1003
27. C.M. Ruiz-Jarabo, A. Arias, E. Baranowski, C. Escarmís, and E. Domingo Memory in viral quasispecies J Virol 74 2000 3543 3547
28. C.M. Ruiz-Jarabo, A. Arias, C. Molina-París, C. Briones, E. Baranowski, C. Escarmís, and E. Domingo Duration and fitness dependence of quasispecies memory J Mol Biol 315 2002 285 296
29. C.M. Ruiz-Jarabo, E. Miller, G. Gómez-Mariano, and E. Domingo Synchronous loss of quasispecies memory in parallel viral lineages: a deterministic feature of viral quasispecies J Mol Biol 333 2003 553 563
30. C. Briones, and E. Domingo Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications AIDS Rev 10 2008 93 109
31. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, and A.J. Muir et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
32. R. Lopez-Rodriguez, A. Hernandez-Bartolome, M.J. Borque, Y. Rodriguez-Munoz, S. Martin-Vilchez, M. Trapero-Marugan, L. Garcia-Buey, P. Munoz de Rueda, L. Rodrigo, and J.R. Vidal-Castineira et al. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy Genes Immun 14 2013 317 324
33. C. Keane, D. O'Shea, T. Reiberger, M. Peck-Radosavljevic, G. Farrell, C. Bergin, and C.M. Gardiner Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection PLoS One 8 2013 e66831
34. H. Qashqari, A. Al-Mars, A. Chaudhary, A. Abuzenadah, G. Damanhouri, M. Alqahtani, M. Mahmoud, M. El Sayed Zaki, K. Fatima, and I. Qadri Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance Infect Genet Evol 19 2013 113 119
35. P. Farci New insights into the HCV quasispecies and compartmentalization Sem Liver Dis 2011 356 374
36. P. Keskinen, K. Melen, and I. Julkunen Expression of HCV structural proteins impairs IFN-mediated antiviral response Virology 299 2002 164 171
37. J. Xu, S. Liu, Y. Xu, P. Tien, and G. Gao Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha Virus Res 141 2009 55 62
38. Y. Funaoka, N. Sakamoto, G. Suda, Y. Itsui, M. Nakagawa, S. Kakinuma, T. Watanabe, K. Mishima, M. Ueyama, and I. Onozuka et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91 J Virol 85 2011 5986 5994
39. R.X. Shao, L. Zhang, L.F. Peng, E. Sun, W.J. Chung, J.Y. Jang, W.L. Tsai, G. Hyppolite, and R.T. Chung Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner J Virol 84 2010 6060 6069
40. V. Pazienza, M. Vinciguerra, A. Andriulli, and A. Mangia Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells J Gen Virol 91 2010 1678 1686
41. G. Suda, N. Sakamoto, Y. Itsui, M. Nakagawa, M. Tasaka-Fujita, Y. Funaoka, T. Watanabe, S. Nitta, K. Kiyohashi, and S. Azuma et al. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones Virology 407 2010 80 90
42. A. El-Shamy, S.R. Kim, Y.H. Ide, N. Sasase, S. Imoto, L. Deng, I. Shoji, and H. Hotta Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy Intervirology 55 2012 1 11
43. S.B. Serre, H.B. Krarup, J. Bukh, and J.M. Gottwein Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance J Virol 87 2013 12776 12793
44. A. El-Shamy, I. Shoji, W. El-Akel, S.E. Bilasy, L. Deng, M. El-Raziky, D.P. Jiang, G. Esmat, and H. Hotta NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients J Clin Microbiol 50 2012 3886 3892
45. A. El-Shamy, I. Shoji, S.R. Kim, Y. Ide, S. Imoto, L. Deng, S. Yoon, T. Fujisawa, S. Tani, and Y. Yano et al. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy PLoS One 7 2012 e30513
46. A. El-Shamy, I. Shoji, T. Saito, H. Watanabe, Y.H. Ide, L. Deng, S. Kawata, and H. Hotta Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy Microbiol Immunol 55 2011 418 426
47. A. El-Shamy, M. Nagano-Fujii, N. Sasase, S. Imoto, S.R. Kim, and H. Hotta Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy Hepatology 48 2008 38 47
48. R. Kozuka, M. Enomoto, H. Hai, T. Ogawa, M. Nakaya, A. Hagihara, H. Fujii, S. Kobayashi, S. Iwai, and H. Morikawa et al. Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment Hepatol Res 42 2012 1157 1167
49. N. Akuta, F. Suzuki, Y. Kawamura, H. Yatsuji, H. Sezaki, Y. Suzuki, T. Hosaka, M. Kobayashi, M. Kobayashi, and Y. Arase et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels J Hepatol 46 2007 403 410
50. K. Namba, K. Naka, H. Dansako, A. Nozaki, M. Ikeda, Y. Shiratori, K. Shimotohno, and N. Kato Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype Biochem Biophys Res Commun 323 2004 299 309
51. S.R. Kim, A. El-Shamy, S. Imoto, K.I. Kim, Y.H. Ide, L. Deng, I. Shoji, Y. Tanaka, Y. Hasegawa, M. Ota, and H. Hotta Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load J Gastroenterol 47 2012 1143 1151
52. M. Sanjo, T. Saito, R. Ishii, Y. Nishise, H. Haga, K. Okumoto, J. Ito, H. Watanabe, K. Saito, and H. Togashi et al. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C J Med Virol 82 2010 1364 1370
53. K. Sugimoto, S.R. Kim, A. El-Shamy, S. Imoto, K. Ando, K.I. Kim, Y. Tanaka, Y. Yano, S.K. Kim, and Y. Hasegawa et al. Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance Dig Dis (Basel, Switzerland) 31 2013 421 425
54. A. El-Shamy, M. Shindo, I. Shoji, L. Deng, T. Okuno, and H. Hotta Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma Hepatology 58 2013 555 563
55. C. Perales, N.M. Beach, I. Gallego, M.E. Soria, J. Quer, J.I. Esteban, C. Rice, E. Domingo, and J. Sheldon Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype J Virol 87 2013 7593 7607
56. S. Marukian, C.T. Jones, L. Andrus, M.J. Evans, K.D. Ritola, E.D. Charles, C.M. Rice, and L.B. Dustin Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells Hepatology 48 2008 1843 1850